Pfizer Inc. and Eli Lilly and Co. are preparing to resume the phase III program for their partnered pain candidate, tanezumab, that has been in limbo since 2010, when the FDA raised concerns about a small number of osteoarthritis (OA) patients in the tanezumab program whose OA worsened, necessitating joint replacement.